[8-K] Aprea Therapeutics, Inc. Common stock Reports Material Event
Aprea Therapeutics furnished a press release that announces its financial results for the three- and six-month periods ended June 30, 2025 and provided an operational update. The press release is attached as Exhibit 99.1 and the company also updated its corporate presentation, filed as Exhibit 99.2. The Form 8-K states that the information in Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
The 8-K itself does not include the underlying financial figures or metrics; it notifies investors that the detailed results and presentation materials are available in the referenced exhibits.
Aprea Therapeutics ha pubblicato un comunicato stampa con i risultati finanziari per i periodi di tre e sei mesi conclusi il 30 giugno 2025 e ha fornito un aggiornamento operativo. Il comunicato 猫 allegato come Exhibit 99.1 e la societ脿 ha inoltre aggiornato la propria presentazione aziendale, depositata come Exhibit 99.2. Il Form 8-K specifica che le informazioni contenute nell'Item 2.02 e nell'Exhibit 99.1 sono state fornite e non devono essere considerate "filed" ai fini della Sezione 18 dell'Exchange Act.
Lo stesso 8-K non riporta i dati finanziari o le metriche sottostanti; informa gli investitori che i risultati dettagliati e il materiale della presentazione sono disponibili negli exhibit citati.
Aprea Therapeutics public贸 un comunicado de prensa que anuncia sus resultados financieros para los periodos de tres y seis meses finalizados el 30 de junio de 2025 y ofreci贸 una actualizaci贸n operativa. El comunicado se adjunta como Exhibit 99.1 y la compa帽铆a tambi茅n actualiz贸 su presentaci贸n corporativa, presentada como Exhibit 99.2. El Form 8-K indica que la informaci贸n en el Item 2.02 y en el Exhibit 99.1 se est谩 proporcionando y no deber谩 considerarse "filed" a efectos de la Secci贸n 18 del Exchange Act.
El propio 8-K no incluye las cifras financieras ni las m茅tricas subyacentes; notifica a los inversores que los resultados detallados y los materiales de la presentaci贸n est谩n disponibles en los exhibits referenciados.
Aprea Therapeutics電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 6臧滌洈 旮瓣皠鞚� 鞛 瓴瓣臣毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚绊彫頃橁碃 鞖挫榿 順勴櫓鞚� 鞐呺嵃鞚错姼頄堨姷雼堧嫟. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅�, 須岇偓電� 旮办梾 頂勲爤鞝犿厡鞚挫厴霃� Exhibit 99.2搿� 臧膘嫚頃橃棳 鞝滌稖頄堨姷雼堧嫟. Form 8-K鞐愲姅 Item 2.02 氚� Exhibit 99.1鞚� 鞝曤炒臧� 鞝滉车霅� 瓴冹澊氅� Exchange Act鞚� 靹轨厴 18 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婋姅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 8-K 鞛愳泊鞐愲姅 旮半掣 鞛 靾橃箻雮� 歆�響滉皜 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 靸侅劯 瓴瓣臣鞕� 頂勲爤鞝犿厡鞚挫厴 鞛愲電� 彀胳“霅� 鞝勳嫓氍�(exhibits)鞐愳劀 頇曥澑頃� 靾� 鞛堨潓鞚� 韴瀽鞛愳棎瓴� 鞎岆Μ瓿� 鞛堨姷雼堧嫟.
Aprea Therapeutics a publi茅 un communiqu茅 de presse annon莽ant ses r茅sultats financiers pour les p茅riodes de trois et six mois cl么tur茅es le 30 juin 2025 et a communiqu茅 une mise 脿 jour op茅rationnelle. Le communiqu茅 est joint en tant que Exhibit 99.1 et la soci茅t茅 a 茅galement mis 脿 jour sa pr茅sentation d'entreprise, d茅pos茅e en tant que Exhibit 99.2. Le formulaire 8-K pr茅cise que les informations figurant 脿 l'Item 2.02 et dans l'Exhibit 99.1 sont fournies et ne doivent pas 锚tre consid茅r茅es comme "filed" aux fins de la Section 18 de l'Exchange Act.
Le 8-K lui-m锚me n'inclut pas les chiffres financiers ou les indicateurs sous-jacents ; il informe les investisseurs que les r茅sultats d茅taill茅s et les documents de pr茅sentation sont disponibles dans les exhibits mentionn茅s.
Aprea Therapeutics ver枚ffentlichte eine Pressemitteilung, in der die Finanzergebnisse f眉r die drei- und sechsmonatigen Zeitr盲ume zum 30. Juni 2025 bekannt gegeben werden, und gab ein Betriebsupdate. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt, und das Unternehmen hat seine Unternehmenspr盲sentation als Exhibit 99.2 aktualisiert. Im Form 8-K hei脽t es, dass die Informationen in Item 2.02 und in Exhibit 99.1 bereitgestellt wurden und f眉r Zwecke von Section 18 des Exchange Act nicht als "filed" gelten sollen.
Das 8-K selbst enth盲lt keine zugrundeliegenden Finanzzahlen oder Kennzahlen; es informiert die Anleger lediglich dar眉ber, dass die detaillierten Ergebnisse und Pr盲sentationsunterlagen in den genannten Exhibits verf眉gbar sind.
- None.
- None.
Insights
TL;DR: Routine earnings release and deck update; exhibits furnished but the 8-K contains no financial figures.
The filing indicates the company issued a press release disclosing results for the three- and six-month periods ended June 30, 2025 and updated its investor presentation. Because the company expressly states the press release is "furnished, not filed," the disclosure follows common practice for earnings releases and limits Section 18 liability. Investors should review Exhibits 99.1 and 99.2 for the substantive financial metrics and context; the 8-K serves as a notice rather than the primary source of numbers.
TL;DR: Standard corporate disclosure; CEO signed the filing and exhibits are provided for investor review.
The Form 8-K documents routine communications: a press release with interim financial results and an updated corporate presentation. The report identifies Exhibits 99.1 and 99.2 and is signed by the President and CEO, Oren Gilad, Ph.D. There are no indications in the filing of leadership changes, material transactions, or governance concerns. The notation that the materials are furnished rather than filed is a procedural disclosure that is consistent with established practice.
Aprea Therapeutics ha pubblicato un comunicato stampa con i risultati finanziari per i periodi di tre e sei mesi conclusi il 30 giugno 2025 e ha fornito un aggiornamento operativo. Il comunicato 猫 allegato come Exhibit 99.1 e la societ脿 ha inoltre aggiornato la propria presentazione aziendale, depositata come Exhibit 99.2. Il Form 8-K specifica che le informazioni contenute nell'Item 2.02 e nell'Exhibit 99.1 sono state fornite e non devono essere considerate "filed" ai fini della Sezione 18 dell'Exchange Act.
Lo stesso 8-K non riporta i dati finanziari o le metriche sottostanti; informa gli investitori che i risultati dettagliati e il materiale della presentazione sono disponibili negli exhibit citati.
Aprea Therapeutics public贸 un comunicado de prensa que anuncia sus resultados financieros para los periodos de tres y seis meses finalizados el 30 de junio de 2025 y ofreci贸 una actualizaci贸n operativa. El comunicado se adjunta como Exhibit 99.1 y la compa帽铆a tambi茅n actualiz贸 su presentaci贸n corporativa, presentada como Exhibit 99.2. El Form 8-K indica que la informaci贸n en el Item 2.02 y en el Exhibit 99.1 se est谩 proporcionando y no deber谩 considerarse "filed" a efectos de la Secci贸n 18 del Exchange Act.
El propio 8-K no incluye las cifras financieras ni las m茅tricas subyacentes; notifica a los inversores que los resultados detallados y los materiales de la presentaci贸n est谩n disponibles en los exhibits referenciados.
Aprea Therapeutics電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 6臧滌洈 旮瓣皠鞚� 鞛 瓴瓣臣毳� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚绊彫頃橁碃 鞖挫榿 順勴櫓鞚� 鞐呺嵃鞚错姼頄堨姷雼堧嫟. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅�, 須岇偓電� 旮办梾 頂勲爤鞝犿厡鞚挫厴霃� Exhibit 99.2搿� 臧膘嫚頃橃棳 鞝滌稖頄堨姷雼堧嫟. Form 8-K鞐愲姅 Item 2.02 氚� Exhibit 99.1鞚� 鞝曤炒臧� 鞝滉车霅� 瓴冹澊氅� Exchange Act鞚� 靹轨厴 18 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婋姅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 8-K 鞛愳泊鞐愲姅 旮半掣 鞛 靾橃箻雮� 歆�響滉皜 韽暔霅橃柎 鞛堨 鞎婌溂氅�, 靸侅劯 瓴瓣臣鞕� 頂勲爤鞝犿厡鞚挫厴 鞛愲電� 彀胳“霅� 鞝勳嫓氍�(exhibits)鞐愳劀 頇曥澑頃� 靾� 鞛堨潓鞚� 韴瀽鞛愳棎瓴� 鞎岆Μ瓿� 鞛堨姷雼堧嫟.
Aprea Therapeutics a publi茅 un communiqu茅 de presse annon莽ant ses r茅sultats financiers pour les p茅riodes de trois et six mois cl么tur茅es le 30 juin 2025 et a communiqu茅 une mise 脿 jour op茅rationnelle. Le communiqu茅 est joint en tant que Exhibit 99.1 et la soci茅t茅 a 茅galement mis 脿 jour sa pr茅sentation d'entreprise, d茅pos茅e en tant que Exhibit 99.2. Le formulaire 8-K pr茅cise que les informations figurant 脿 l'Item 2.02 et dans l'Exhibit 99.1 sont fournies et ne doivent pas 锚tre consid茅r茅es comme "filed" aux fins de la Section 18 de l'Exchange Act.
Le 8-K lui-m锚me n'inclut pas les chiffres financiers ou les indicateurs sous-jacents ; il informe les investisseurs que les r茅sultats d茅taill茅s et les documents de pr茅sentation sont disponibles dans les exhibits mentionn茅s.
Aprea Therapeutics ver枚ffentlichte eine Pressemitteilung, in der die Finanzergebnisse f眉r die drei- und sechsmonatigen Zeitr盲ume zum 30. Juni 2025 bekannt gegeben werden, und gab ein Betriebsupdate. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt, und das Unternehmen hat seine Unternehmenspr盲sentation als Exhibit 99.2 aktualisiert. Im Form 8-K hei脽t es, dass die Informationen in Item 2.02 und in Exhibit 99.1 bereitgestellt wurden und f眉r Zwecke von Section 18 des Exchange Act nicht als "filed" gelten sollen.
Das 8-K selbst enth盲lt keine zugrundeliegenden Finanzzahlen oder Kennzahlen; es informiert die Anleger lediglich dar眉ber, dass die detaillierten Ergebnisse und Pr盲sentationsunterlagen in den genannten Exhibits verf眉gbar sind.
FAQ
What did Aprea Therapeutics (APRE) disclose in this Form 8-K?
Does the Form 8-K include the actual financial figures for Q2 2025?
Are the press release and presentation "filed" with the SEC?
Which exhibits should investors consult for the detailed disclosure?
Who signed the Form 8-K for Aprea Therapeutics?
On which exchange is Aprea Therapeutics common stock listed and what is the ticker?
